公开(公告)号：US20030026786A1

公开(公告)日：2003-02-06

申请号：US09319521

申请日：1999-06-04

发明人： MARK F. PITTENGER ,  ALASTAIR M. MACKAY ,  J. MARY MURPHY ,  FRANCIS P. BARRY

IPC分类号： A01N001/00 ,  A01N001/02 ,  A01N063/00 ,  A01N065/00 ,  C12N005/00 ,  C12N005/02 ,  C12N005/08 ,  A61K035/34 ,  A61K035/12 ,  A61K035/26 ,  A61K035/28 ,  C07K001/00

CPC分类号： C12N5/0655 ,  C12N2500/24 ,  C12N2500/38 ,  C12N2500/90 ,  C12N2501/105 ,  C12N2501/15 ,  C12N2501/33

摘要： Disclosed are a composition of chemically defined components having elevated levels of simple sugars which support the enhanced in vitro chondrogenesis of mesenchymal progenitor cells, a method for in vitro chondrogenic induction of such progenitor cells and a method of forming human chondrocytes in vitro from such progenitor cells.

摘要翻译： 公开了具有升高水平的简单糖的组成，其具有支持间充质祖细胞增强的体外软​​骨形成，这种祖细胞的体外软骨形成诱导的方法以及从这种祖细胞体外形成人软骨细胞的方法 。

公开(公告)号：US20030007957A1

公开(公告)日：2003-01-09

申请号：US09898316

申请日：2001-07-03

发明人： Calvin Britton ,  Alex Dellinger ,  Jim Limbird ,  Carl Keller ,  Charles Worden JR.

IPC分类号： A01N063/00 ,  A01N065/00 ,  A01N001/02 ,  A61K035/14 ,  A61K035/16

CPC分类号： A61L26/008 ,  A61K35/16 ,  A61L15/225 ,  A61L15/40 ,  A61L15/60 ,  A61L26/0052 ,  A61L26/0057 ,  A61K2300/00 ,  C08L1/00 ,  C08L5/00

摘要： A wound care preparation free from bovine-derived activating agents is disclosed for use in wound care, for both topical wounds and surgical wounds. The preparation is isolated by first obtaining an amount of whole blood from the patient and treating the whole blood with one or more anti-clotting agents, subjecting the whole blood to a centrifugation process to obtain an amount of platelet-rich plasma, adding to the platelet-rich plasma an amount of anti-clotting neutralizing agent, and mixing the platelet-rich plasma with a structural matrix to increase viscosity of the preparation. In use, the viscous preparation can be applied directly to a wound or surgery incision and the viscous preparation may be mixed with other wound healing agents, growth matrices, or promoters such as anti-fungal agents, anti-biotic agents, and preservatives.

公开(公告)号：US20020192190A1

公开(公告)日：2002-12-19

申请号：US09226742

申请日：1999-01-07

发明人： PAUL P. LATTA

IPC分类号： A61K038/28 ,  A61K039/38 ,  A01N063/00 ,  A01N065/00 ,  A61K039/00 ,  C12N005/00 ,  C12N005/02 ,  A61F002/00 ,  A61K009/48 ,  A61K009/14 ,  C12N001/00

CPC分类号： A61K35/39 ,  A61K9/0024 ,  A61K9/5031 ,  A61K39/0008 ,  A61K39/001 ,  A61K2035/122 ,  A61K2035/128 ,  A61K2039/515 ,  C12N5/0677

摘要： A method of creating tolerance to transplanted cells, tissue, or organs without the need for continuous immunosuppression. A tolerizing dose of a cell or tissue within a membrane structure is implanted into a patient. Once the patient becomes tolerant to the cell or tissue, a tissue or organ is implanted which will no longer be recognized as foreign matter. The method makes animal organs practical for human use, prevents autoimmune destruction as well as immune rejection. It has applications in treatment and prevention of many mammalian diseases.

摘要翻译： 一种产生对移植细胞，组织或器官的耐受性而不需要连续免疫抑制的方法。 将膜结构内的细胞或组织的耐受剂量植入患者体内。 一旦患者变得对细胞或组织变得容忍，植入将不再被识别为异物的组织或器官。 该方法使动物器官适用于人类，防止自身免疫破坏以及免疫排斥。 它具有治疗和预防许多哺乳动物疾病的应用。

公开(公告)号：US20020192185A1

公开(公告)日：2002-12-19

申请号：US10046938

申请日：2002-01-14

发明人： Suresh K. Mittal ,  Frank L. Graham ,  Ludvik Prevec ,  Lorne A. Babiuk

IPC分类号： A61K048/00 ,  A61K039/235 ,  C12N007/00 ,  C12N015/861 ,  A01N063/00 ,  A61K039/23 ,  C12N007/01 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C12N015/86 ,  A61K039/12

CPC分类号： C12N15/86 ,  A61K48/00 ,  C07K14/005 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10352

摘要： The present invention relates novel live bovine adenovirus (BAV) expression vector systems in which part or all of one or both of the early region 1 (E1) and early region 3 (E3) genes are deleted and replaced by a foreign gene or fragment thereof and novel recombinant mammalian cell lines stably transformed with BAV E1 sequences, and therefore, express E1 gene products capable of allowing replication therein of a bovine adenovirus having an E1 deletion replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof and their use in production of (antigenic) polypeptides or fragments thereof for the purpose of live recombinant virus or subunit vaccine or for other therapies.

摘要翻译： 本发明涉及新鲜活牛腺病毒（BAV）表达载体系统，其中早期区域1（E1）和早期区域3（E3）基因中的一个或两个的部分或全部缺失并被外源基因或其片段替代 以及用BAV E1序列稳定转化的新型重组哺乳动物细胞系，因此表达能够允许在其中复制具有E1缺失的牛腺病毒的E1基因产物，其被编码外源基因或其片段的异源核苷酸序列替代，以及它们在 用于活重组病毒或亚单位疫苗或用于其他疗法的（抗原性）多肽或其片段的产生。

公开(公告)号：US20020187135A1

公开(公告)日：2002-12-12

申请号：US09164568

申请日：1998-10-01

发明人： RANDOLPH J. NOELLE ,  TERESA M. FOY ,  FIONA H. DURIE

IPC分类号： A61K038/16 ,  A01N063/00 ,  A61K039/395 ,  A61K039/40 ,  A61K039/42 ,  A61K039/00 ,  A61K039/38 ,  C07K001/00 ,  C07K014/00 ,  C07K017/00 ,  C12P021/08 ,  C07K016/00 ,  A61K035/26 ,  A61K035/28 ,  A01N025/00

CPC分类号： C07K14/70578 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/57 ,  C07K16/2875 ,  C07K19/00 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2319/00 ,  G01N33/6854

摘要： Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand on the antigen presenting cell with the receptor on the T cell. In a preferred embodiment, the cell which presents antigen to the T cell is a B cell and the receptor on the surface of the T cell which mediates contact-dependent helper effector function is gp39. Preferably, the antagonist is an anti-gp39 antibody or a soluble gp39 ligand (e.g., soluble CD40). The methods of the invention can be used to induce T cell tolerance to a soluble antigen or to an allogeneic cell. The methods of the invention can also be used to induce tolerance in cases of bone marrow transplantation and other organ transplants and to inhibit graft-versus-host disease.

摘要翻译： 公开了诱导抗原特异性T细胞耐受性的方法。 所述方法包括使T细胞接触：1）向T细胞呈递抗原的细胞，其中细胞上的配体与介导接触依赖性辅助效应子功能的T细胞表面上的受体相互作用; 和2）T细胞表面上的受体拮抗剂，其抑制抗原呈递细胞上的配体与T细胞上的受体的相互作用。 在优选的实施方案中，向T细胞呈递抗原的细胞是B细胞，介导接触依赖性辅助效应子功能的T细胞表面上的受体是gp39。 优选地，拮抗剂是抗gp39抗体或可溶性gp39配体（例如可溶性CD40）。 本发明的方法可用于诱导对可溶性抗原或同种异体细胞的T细胞耐受性。 本发明的方法还可用于在骨髓移植和其他器官移植的情况下诱导耐受性并抑制移植物抗宿主病。

公开(公告)号：US20020182261A1

公开(公告)日：2002-12-05

申请号：US09996640

申请日：2001-11-28

发明人： Jianwu Dai ,  Eugene Bell ,  Vladimir Russakovsky

IPC分类号： A61K035/54 ,  A61K035/12 ,  A01N063/00 ,  C12N011/00

CPC分类号： C12N5/0602 ,  A61K35/44 ,  A61K38/1875 ,  A61L27/3604 ,  A61L27/3625 ,  A61L27/3683 ,  A61L27/3687 ,  A61L27/3691 ,  A61L27/3834 ,  A61L2430/40 ,  C12N2533/90 ,  C12N2537/00 ,  C12N2537/10

摘要： A method of forming and preserving a bioremodelable, biopolymer scaffold material by subjecting animal tissue to chemical and mechanical processing. In addition to skin tissue, another source of EBM is a blood vessel. EBM may be used for hernia repair, colon, rectal, vaginal and or urethral prolapse treatment; pelvic floor reconstruction; muscle flap reinforcement; lung tissue support; rotator cuff repair or replacement; periosteum replacement; dura repair; pericardial membrane repair; soft tissue augmentation; intervertebral disk repair; and periodontal repair. EBM may also be used as a urethral sling, laminectomy barrier or spinal fusion device.

摘要翻译： 通过使动物组织进行化学和机械加工来形成和保存生物可重塑的生物聚合物支架材料的方法。 除皮肤组织外，EBM的另一个来源是血管。 EBM可用于疝修补，结肠，直肠，阴道和/或尿道脱垂治疗; 盆底重建; 肌肉瓣增强; 肺组织支撑; 肩袖修复或更换; 骨膜替代; 硬脑膜修复 心包膜修复; 软组织增大; 椎间盘修复; 和牙周修复。 EBM也可用作尿道吊带，椎板切除术障碍或脊柱融合装置。

公开(公告)号：US20020168349A1

公开(公告)日：2002-11-14

申请号：US09916510

申请日：2001-07-30

发明人： Richard Iggo ,  Michele Alberto Brunori

IPC分类号： A61K048/00 ,  C12N007/00 ,  C07H021/04 ,  A01N063/00 ,  C12N007/01

CPC分类号： C12N15/86 ,  A61K35/13 ,  A61K48/0066 ,  C07K14/005 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2799/021 ,  C12N2800/204 ,  C12N2800/206 ,  C12N2830/00 ,  C12N2830/008 ,  Y02A50/467

摘要： A viral DNA construct, and virus encoded thereby, is provided having one or more tumor specific transcription factor binding sites in place of one or more wild type transcription factor binding sites operatively positioned in the promoter region which controls expression of early genes responsible for viral nucleic acid replication. Preferred constructs place the tumor specific transcription factor binding sites in operative relation to DNA polymerase, DNA terminal protein and/or DNA binding protein. Compositions and constructs contained therein are provided, particularly for use in therapy. Methods of treating patients for neoplasms are also provided.

摘要翻译： 提供病毒DNA构建体和由此编码的病毒，其具有一个或多个肿瘤特异性转录因子结合位点，以代替可操作地位于启动子区域中的一个或多个野生型转录因子结合位点，其控制负责病毒核酸的早期基因的表达 酸复制。 优选的构建体将肿瘤特异性转录因子结合位点与DNA聚合酶，DNA末端蛋白和/或DNA结合蛋白具有操作关系。 提供其中包含的组合物和构建体，特别用于治疗。 还提供了治疗患者肿瘤的方法。

公开(公告)号：US20020164787A1

公开(公告)日：2002-11-07

申请号：US09998212

申请日：2001-12-03

发明人： Shau-Chi Chi

IPC分类号： C12Q001/70 ,  A01N063/00 ,  A01N065/00 ,  A61K048/00 ,  C12N007/02 ,  C12N005/00 ,  C12N005/02

CPC分类号： C12N7/00 ,  A61K2039/5252 ,  A61K2039/542 ,  C07K16/08 ,  C12N2770/30051 ,  C12Q1/02 ,  C12Q1/701 ,  G01N33/56983

摘要： The present invention describes (1) an immortal cell line derived from grouper and a method for establishing the cell line; (2) methods for mass producing and purifying aquatic 10 viruses using the immortal cell line from grouper; (3) an anti-NNV antibody and a method for producing the anti-NNV antibody; and (4) a vaccine of NNV and a method for protecting fish against NNV infection. The present immortal cell line is derived from the grouper and is susceptible to the viral families of Birnaviridae such as Infectious Pancreatic Necrosis Virus (IPNV); Herpesviridae such as Eel Herpes Virus Formosa (EHVF); Reoviridae such as Hard Clam Reovirus (HCRV); and Nodaviridae such as Nervous Necrosis Virus (NNV).

摘要翻译： 本发明描述了（1）从石斑鱼衍生的永生细胞系和建立细胞系的方法; （2）使用来自石斑鱼的永生细胞系大规模生产和净化水生10种病毒的方法; （3）抗-NNV抗体和制备抗-NNV抗体的方法; 和（4）NNV疫苗和保护鱼类免受NNV感染的方法。 本发明的永生细胞系衍生自石斑鱼，易感染传染性胰腺坏死病毒（IPNV）等Birnaviridae病毒家族; 疱疹病毒科如鳗疱疹病毒（EHVF）; 狂犬病病毒科，如硬蜱呼肠孤病毒（HCRV）; 和Nodaviridae如神经坏死病毒（NNV）。

公开(公告)号：US20020164356A1

公开(公告)日：2002-11-07

申请号：US10128628

申请日：2002-04-23

发明人： Teshome Mebatsion

IPC分类号： A61K048/00 ,  A01N063/00 ,  A61K039/12 ,  C12N007/04

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/205 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/542 ,  C07K14/005 ,  C12N2760/20122 ,  C12N2760/20134 ,  C12N2760/20161

摘要： The present invention describes recombinant RV mutants comprising a combined mutation in two different parts of the viral genome, involving the P and the G genes. The mutations in the P gene preferably encompass residues 139 to 170, more preferably residues 139 to 149, most preferably residues 143-149. The mutation can be a substitution or deletion of one or more amino acids in the above region, as well as combinations of deletion and substitution. Preferred mutants according to the invention may be obtained by deleting residues 143 to 149 or 139 to 149 of the phosphoprotein (P) of rabies virus and simultaneously replacing the Arg at position 333 of the glycoprotein into another residue, preferably Asp instead of Arg. Surprisingly, when these mutations were introduced into rabies viruses lacking Arg at position 333 of their G protein, a dramatic reduction in pathogenicity for suckling mice was observed. This unexpected finding has a profound advantage in developing more safe live attenuated rabies vaccines. The mutation in the G gene may comprise a mutation of the Arg333 codon into a codon that differs by one, two or three nucleotides from said Arg333 codon. Preferably the mutants are mutants of a RV strain in which all three nucleotides of the Arg333 codon are substituted.

摘要翻译： 本发明描述了重组RV突变体，其包含病毒基因组的两个不同部分中的组合突变，涉及P和G基因。 P基因中的突变优选包括残基139至170，更优选残基139至149，最优选残基143-149。 突变可以是上述区域中一个或多个氨基酸的取代或缺失，以及缺失和取代的组合。 根据本发明的优选突变体可以通过删除狂犬病病毒的磷蛋白（P）的143至149或139至149位，同时将糖蛋白333位的Arg同时替换为另一残基，优选Asp而不是Arg来获得。 令人吃惊的是，当这些突变引入到其G蛋白333位缺乏Arg的狂犬病病毒时，观察到乳鼠的致病性显着降低。 这种意想不到的发现在开发更安全的减毒狂犬病疫苗方面具有深远的优势。 G基因中的突变可以包括Arg333密码子的突变成从所述Arg333密码子不同一个，两个或三个核苷酸的密码子。 优选地，突变体是其中Arg333密码子的所有三个核苷酸都被取代的RV菌株的突变体。

公开(公告)号：US20020155582A1

公开(公告)日：2002-10-24

申请号：US09747419

申请日：2000-12-23

发明人： Stanley M. Lemon ,  MinKyung Yi

IPC分类号： A61K048/00 ,  C12N007/01 ,  C12N015/861 ,  C07H021/04 ,  A01N063/00 ,  A61K039/42 ,  C12N007/00 ,  C12N015/86

CPC分类号： C12N7/00 ,  A61K48/00 ,  C12N15/86 ,  C12N2770/24243 ,  C12N2840/203

摘要： The present invention provides a replication competent hepatitis C virus that includes a heterologous polynucleotide present in the 3null non-translated RNA. The invention also includes methods for modifying a hepatitis C virus, selecting a replication competent hepatitis C virus, detecting a replication competent hepatitis C virus, and identifying a compound that inhibits replication of a hepatitis C virus.

摘要翻译： 本发明提供了一种复制感染性丙型肝炎病毒，其包含存在于3'非翻译RNA中的异源多核苷酸。 本发明还包括改变丙型肝炎病毒，选择复制感染型丙型肝炎病毒，检测可复制的丙型肝炎病毒以及鉴定抑制丙型肝炎病毒复制的化合物的方法。